Alzheimer's Disease clinical trials at UCLA
15 in progress, 7 open to eligible people
[18F]PI-2620 Phase 3 Histopathological Study
open to eligible people ages 50 years and up
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime …
Los Angeles, California and other locations
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
open to eligible people ages 60-100
The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work…
Los Angeles, California
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
open to eligible people ages 50-90
The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild…
Los Angeles, California
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
open to eligible people ages 50-90
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Los Angeles, California and other locations
Alzheimer's Disease Neuroimaging Initiative 4
open to eligible people ages 55-90
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2,…
Los Angeles, California and other locations
Longitudinal Early-onset Alzheimer's Disease Study Protocol
open to eligible people ages 40-64
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging,…
Los Angeles, California and other locations
Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
open to eligible people ages 18 years and up
This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, …
Los Angeles, California and other locations
Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Sorry, in progress, not accepting new patients
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which…
Los Angeles, California and other locations
JNJ-63733657 in Participants With Early Alzheimer's Disease
Sorry, in progress, not accepting new patients
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Los Angeles, California and other locations
Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Sorry, in progress, not accepting new patients
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum …
Los Angeles, California and other locations
Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Sorry, in progress, not accepting new patients
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow…
Los Angeles, California and other locations
Epileptic Hippocampus in Alzheimer's Disease
Sorry, not yet accepting patients
The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB …
Los Angeles, California
Escitalopram for Agitation in Alzheimer's Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Los Angeles, California and other locations
Care Ecosystem Consortium Effectiveness Study
Sorry, in progress, not accepting new patients
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by…
Torrance, California and other locations
Diabetes Prevention Program Outcomes Study AD/ADRD Project
Sorry, accepting new patients by invitation only
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment…
Alhambra, California and other locations
Our lead scientists for Alzheimer's Disease research studies include Susan Y. Bookheimer, PhD Keith A Vossel, MD, MSc Maryam R. Beigi, MD Pauline Wu, DO Daniel H. Silverman, MD, PhD Mario F. Mendez, MD, PhD.
Last updated: